MAB Sample Clauses

MAB. ZymoGenetics developed a fully-human anti-IL-21 monoclonal antibody, or IL-21 mAb, as a potential therapeutic treatment for autoimmune and chronic inflammatory disorders. Cell biology experiments and preclinical models of inflammatory diseases suggest that IL-21 is a key mediator of inflammation, and over-expression patterns of IL-21 and its receptor in inflamed tissues of human diseases, such as in inflammatory bowel disease, rheumatoid arthritis and lupus, further support the role of IL-21 in the disease process. ZymoGenetics is focused on the creation of novel protein drugs to improve patient care and address unmet medical needs. The company’s strategy is to discover, develop and commercialize its products independently, in collaboration with partner companies or through out-licensing. ZymoGenetics developed and markets RECOTHROM® Thrombin, topical (Recombinant). The company is developing a proprietary portfolio of immune-based product candidates. PEG-Interferon lambda is a novel type-3 interferon in clinical development for the treatment of chronic hepatitis C infection. Interleukin-21 is a novel cytokine in clinical development for the treatment of metastatic melanoma and renal cell carcinoma. Several other proprietary product candidates are in preclinical development. In addition, ZymoGenetics has licensed rights to multiple clinical and preclinical drug candidates being developed by other companies. For further information, visit ▇▇▇.▇▇▇▇▇▇▇▇▇▇▇▇.▇▇▇. Novo Nordisk is a healthcare company and a world leader in diabetes care. In addition, Novo Nordisk has a leading position within areas such as haemostasis management, growth hormone therapy and hormone replacement therapy. Novo Nordisk manufactures and markets pharmaceutical products and services that make a significant difference to patients, the medical profession and society. With headquarters in Denmark, Novo Nordisk employs more than 28,500 employees in 81 countries, and markets its products in 179 countries. Novo Nordisk’s B shares are listed on the stock exchanges in Copenhagen and London. Its ADRs are listed on the New York Stock Exchange under the symbol ‘NVO’. For more information, visit ▇▇▇▇▇▇▇▇▇▇▇.▇▇▇.

MAB. The Man and the Biosphere (MAB) Programme is an intergovernmental scientific programme aiming to set a scientific basis for the improvement of the relationships between people and their environment globally. The MAB Programme proposes an interdisciplinary research agenda and capacity building that target the ecological, social and economic dimensions of biodiversity loss and the reduction of this loss. It’s World Network of Biosphere Reserves currently counts more than 700 biosphere reserves in 130+countries. Concerned with problems at the interface of scientific, environmental, societal and development issues, MAB combines natural and social sciences, economics and education to improve human livelihoods and safeguard natural ecosystems, thus promoting innovative approaches to economic development that is socially and culturally appropriate and environmentally sustainable. ▇▇▇▇ currently supports a project on mangrove restauration in biosphere reserves in the LAC region. Another example is the Be- Resilient Project, which is about climate observations in biosphere reserves and a bridge between the IHP and the MAB.